Evaluation of Clinical Outcomes and Toxicities in Multiple Myeloma Patients Receiving Commercial Talquetamab

被引：0
|
作者：
Lu, Rebecca [1 ]
Chen, Jessica [1 ]
Ow, Karla [1 ]
Hildebrandt, Michelle [1 ]
Huen, Auris [1 ]
Cardoso, Richard [1 ]
Chambers, Mark [1 ]
Abreu, Michelly [1 ]
Cuellar, Elizabeth [1 ]
Ighovoyivwi, Efe [1 ]
Knight, Sarah [1 ]
Santiago, Minifrida [1 ]
Savoie, Cecilia [1 ]
Varghese, Jaimole [1 ]
Zachariah, Annie [1 ]
Becnel, Melody [1 ]
Gaballa, Mahmoud [1 ]
Orlowski, Robert [1 ]
Patel, Krina [1 ]
Pasvolsky, Oren [1 ]
Thomas, Sheeba [1 ]
Ye, Jing Christine [1 ]
Weber, Donna [1 ]
Lee, Hans [1 ]
Richards, Tiffany [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NSO-04
引用
收藏
页码：S281 / S281
页数：1
相关论文
共 50 条
  • [1] Treatment Outcomes of Primary vs. Referred Patients with Multiple Myeloma Receiving Talquetamab or Teclistamab
    Fries, Gina
    Alshlah, Ali
    Baran, Andrea
    Lipe, Brea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S110 - S110
  • [2] Use of Baseline Inflammatory Markers to Predict Toxicities Among Relapsed/Refractory Multiple Myeloma Patients Receiving Ambulatory Teclistamab and Talquetamab
    Tabbara, Nadeem
    Singel, Michael
    Allen, Natalie
    Shedeck, Audra
    Mooney, Kathy
    Campion, Kathryn
    Raymond, Callan
    Sabirzhanova, Inna
    Anderson, Karen
    Waheed, Sarah
    Huff, Carol Ann
    Ali, Syed Abbas
    Gocke, Christian B.
    Imus, Philip
    BLOOD, 2024, 144 : 7232 - 7233
  • [3] Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
    Chari, Ajai
    Krishnan, Amrita
    Rasche, Leo
    Ye, Jing Christine
    Garfall, Alfred
    Popat, Rakesh
    Lipe, Brea
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara
    Tomlinson, Chalmer
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Smit, M. Damiette
    Gray, Kathleen
    Kane, Colleen
    Heuck, Christoph
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10): : 665 - +
  • [4] Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy
    Mouhieddine, Tarek H.
    dos Santos, Junia Vieira
    Ghodke-Puranik, Yogita
    Aleman, Adolfo
    Melnekoff, David
    Upadhyaya, Bhaskar
    Rahman, Adeeb
    Afik, Shaked
    Lewinsky, Hadas
    Thibaud, Santiago
    Rossi, Adriana C.
    Richard, Shambavi
    Rodriguez, Cesar
    Richter, Joshua
    Cho, Hearn Jay
    Sanchez, Larysa
    Jagannath, Sundar
    Chari, Ajai
    Lagana, Alessandro
    Parekh, Samir
    BLOOD, 2023, 142
  • [5] Ferritin Dynamics are Associated with Clinical Outcomes of Multiple Myeloma Patients Receiving Bispecific Antibodies
    Mouhieddine, Tarek
    Sheng, Tianxiang
    Costa, Bruno
    Saffran, Nathaniel
    Pan, Darren
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Rossi, Adriana
    Cho, Hearn Jay
    Richter, Joshua
    Rodriguez-Valdes, Cesar
    Chari, Ajai
    Parekh, Samir
    Moshier, Erin
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S75 - S75
  • [6] Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
    Ariana Berenson
    Suzie Vardanyan
    Michael David
    James Wang
    Nika Manik Harutyunyan
    Jillian Gottlieb
    Ran Halleluyan
    Tanya M. Spektor
    Kyle A. Udd
    Shahrooz Eshaghian
    Youram Nassir
    Benjamin Eades
    Regina Swift
    James R. Berenson
    Annals of Hematology, 2017, 96 : 449 - 459
  • [7] Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
    Berenson, Ariana
    Vardanyan, Suzie
    David, Michael
    Wang, James
    Harutyunyan, Nika Manik
    Gottlieb, Jillian
    Halleluyan, Ran
    Spektor, Tanya M.
    Udd, Kyle A.
    Eshaghian, Shahrooz
    Nassir, Youram
    Eades, Benjamin
    Swift, Regina
    Berenson, James R.
    ANNALS OF HEMATOLOGY, 2017, 96 (03) : 449 - 459
  • [8] Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
    Catamero, Donna
    Ray, Chloe
    Purcell, Kiah
    Leahey, Sheryl
    Esler, Elaine
    Rogers, Stephanie
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    Tolbert, Jaszianne
    Renaud, Thomas
    Patel, Saurabh
    Hannemann, Linda
    Shenoy, Samantha
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (05)
  • [9] NURSING CONSIDERATIONS FOR TALQUETAMAB DOSING IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Blazquez, Patricia
    Chari, Ajai
    Renaud, Thomas
    Tolbert, Jaszianne
    Gray, Kathleen
    Catamero, Donna
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [10] Oral Symptom Assessment Using Patient Reported Outcomes (PRO) for Relapsed Multiple Myeloma Patients Treated with Talquetamab
    Popat, Rakesh
    Greenwood, Alexandra
    Wilson, William
    Mactier, Catriona
    Cerner, Aviva
    Worthington, Sarah
    Russell, Jennifer
    Jenkins, Chloe
    Hughes, Daniel
    Boyle, Eileen
    McMillan, Annabel
    Yong, Kwee
    Lee, Lydia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S123 - S123
12345